Human anti-chimeric antibodies (or HACA) may neutralise and obvious the antibody from your blood circulation, preventing it from reaching tumour sites and reducing efficacy; HACA, therefore, should be monitored and correlated with clinical readouts. == Clinical management of potential toxicities and interventions == Reliable clinical interventions to counter the effects of any anaphylactic responses to medicines and monoclonal antibody therapeutics should be included in the preparation and risk management of clinical trials [89]. of solid tumours such as ovarian and breast carcinomas. Our laboratory has examined this concept by evaluating two chimaeric antibodies of the same specificity (MOv18) but different isotype, an IgG1 and an IgE against the tumour antigen folate receptor (FR). The latter demonstrates the potency of IgE to mount superior immune responses against tumours in disease-relevant models. We recognized Fc receptor-expressing cells, monocytes/macrophages and eosinophils, activated by MOv18 IgE to kill tumour cells by mechanisms such as ADCC and ADCP. We also applied this notion to a marketed therapeutic, the humanised IgG1 antibody trastuzumab and designed an IgE counterpart, which retained the functions of trastuzumab in restricting proliferation of HER2/neu-expressing tumour cells but also activated effector cells to kill tumour cells by different mechanisms. On-going efficacy, security evaluations and future first-in-man clinical studies of IgE therapeutics constitute important metrics for this concept, providing new scope for antibody immunotherapies for solid tumours. Keywords:IgE, Tumour immunotherapy, FR/FBP, Monocytes/macrophages, MOv18 IgE, Allergooncology symposium-in-writing, HER2/neu, IgG, Trastuzumab, Basophils, Eosinophils, Mast cells, Solid tumours, ADCC, ADCP, Ovarian carcinomas, Breast carcinomas == Successes and difficulties for malignancy immunotherapy with antibodies: the case for improving efficacy against solid tumours == Benefiting from their unique specificity for their target antigens, antibodies have been hailed as magic bullets able selectively to seek out and attack tumour cells expressing these antigens [1]. Since the first use of a therapeutic monoclonal antibody in B cell malignancy in the 1980s, the field has benefited from considerable technological improvements and scientific breakthroughs, combined with clinical experience in engineering and translating antibodies into malignancy therapies [2,3]. Antibodies have now earned their place in clinical applications and complement conventional treatments for a number of malignant diseases, with 10 agents approved for the therapy of a handful of indications, and hundreds of others currently undergoing evaluation in clinical trials [1]. It is notable that over half of these successful agents are approved for haematological indications, i.e., leukaemias and lymphomas. Despite the superb specificity and high affinity of antibodies for their target antigens and some significant advances in antibody immunotherapy for breast and colorectal cancers, the concept of a magic bullet for the treatment of many solid tumours has produced less impressive outcomes [4,5]. The human immune system naturally deploys nine antibody classes and subclasses (IgM, IgD, IgG1-4, IgA1, IgA2 and IgE) to perform immune surveillance and to mediate destruction of pathogens in different anatomical compartments. Yet, only IgG (most often IgG1) has been applied in immunotherapy of cancers. One reason may be that IgG antibodies (particularly IgG1) constitute the largest fraction of circulating antibodies in human blood. The choice of antibody class is also based on pioneering work in the late 1980s, comparing a panel PNU-120596 of chimaeric antibodies of the same specificity, each with Fc regions belonging to one of the nine antibody classes and subclasses [6]. Antibodies were evaluated for their ability to bind complement and their potency to mediate haemolysis and cytotoxicity of antigen-expressing target cells in the presence of complement. IgG1 in combination with human peripheral blood mononuclear cells (PBMC) was the most effective IgG subclass in complement-dependent cell killing in vitro, while the IgA and IgE antibodies were completely inert. Subsequent clinical trials with antibodies recognising the B cell marker CD20 supported the inference that IgG1 would be the subclass best suited for immunotherapy of patients with B cell malignancies such as non-Hodgkins lymphoma [7]. Since those studies, comparisons of anti-tumour effects by different antibody classes have been confined to IgG and IgM in both murine models and patients with lymphoid malignancies, while IgA has been shown to mediate ADCC in vitro and in vivo in mouse models PNU-120596 of lymphoma [812]. IgA and IgE antibodies, on the other hand, have never been tested in cancer PNU-120596 patients. Complement-mediated tumour cell death is now known to be only one of several mechanisms by which antibodies may mediate tumour growth restriction [13]. Known mechanisms include engaging immune effector molecules through their Fc regions to induce immune cell-mediated destruction of targeted cells by antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADCP). Antibodies can also act directly on tumour cells to inhibit growth signalling pathways, induce apoptosis, restrict proliferation and cell differentiation of tumour cells, or block tumour cell adhesion and migration. Some antibodies are developed to recognise targets RELA associated with tumour-associated vasculature in order to starve.